➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
McKesson
Boehringer Ingelheim
Moodys
Mallinckrodt

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Molybdenum


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Molybdenum?

Molybdenum is an investigational drug.

There have been 10 clinical trials for Molybdenum. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2016.

The most common disease conditions in clinical trials are Hepatolenticular Degeneration, Metal Metabolism, Inborn Errors, and Iron Overload. The leading clinical trial sponsors are Alexion Pharmaceuticals, Alexion Pharma GmbH, and TRIUMF.

There are fifty-seven US patents protecting this investigational drug and five hundred and thirty international patents.

Recent Clinical Trials for Molybdenum
TitleSponsorPhase
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840Alexion PharmaceuticalsPhase 2
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy ParticipantsAlexion PharmaceuticalsPhase 1
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.Alexion PharmaceuticalsPhase 1

See all Molybdenum clinical trials

Clinical Trial Summary for Molybdenum

Top disease conditions for Molybdenum
Top clinical trial sponsors for Molybdenum

See all Molybdenum clinical trials

US Patents for Molybdenum

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Molybdenum   Try Before You Buy Shaped catalyst for sour gas shift reactions and methods for using them Clariant Corporation (Louisville, KY)   Try Before You Buy
Molybdenum   Try Before You Buy Composite hollow particle, a method for making thereof, and a method for producing hydrogen gas King Abdulaziz University (Jeddah, SA)   Try Before You Buy
Molybdenum   Try Before You Buy Process for producing N-phosphonomethylglycine Monsanto Company (St. Louis, MO)   Try Before You Buy
Molybdenum   Try Before You Buy Overbased additives for lubricant oils containing a molybdenum complex, process for preparing them and compositions containing the said additives Societe Nationale Elf Aquitaine (Courbevoie, FR)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Molybdenum

Drugname Country Document Number Estimated Expiration Related US Patent
Molybdenum China CN105665030 2034-12-08   Try Before You Buy
Molybdenum Austria AT82576 2007-10-26   Try Before You Buy
Molybdenum Australia AU2430288 2007-10-26   Try Before You Buy
Molybdenum Australia AU594589 2007-10-26   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Medtronic
McKesson
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.